rotundifolone: structure in first source
ID Source | ID |
---|---|
PubMed CID | 442497 |
CHEBI ID | 8900 |
SCHEMBL ID | 2317471 |
MeSH ID | M0442088 |
Synonym |
---|
piperitenone oxide |
3564-96-3 |
rotundifolone |
C09896 |
lippione |
(1s,6s)-6-methyl-3-propan-2-ylidene-7-oxabicyclo[4.1.0]heptan-2-one |
6fr5iod112 , |
piperitenone oxide, (+-)- |
cis-piperitenone epoxide |
7-oxabicyclo(4.1.0)heptan-2-one, 6-methyl-3-(1-methylethylidene)-, (1s)- |
unii-6fr5iod112 |
(+-)-rotundifolone |
piperitenone oxide [fhfi] |
fema no. 4199 |
7-oxabicyclo(4.1.0)heptan-2-one, 6-methyl-3-(1-methylethylidene)-, (1s,6s)- |
(+-)-piperitenone oxide |
(+)-piperitenone oxide |
piperitenone oxide, (+)- |
(+)-rotundifolone |
SCHEMBL2317471 |
CHEBI:8900 |
Q27108176 |
DTXSID301317536 |
HY-134013 |
CS-0136507 |
AKOS040753565 |
Excerpt | Reference | Relevance |
---|---|---|
"Rotundifolone elicits an increase in the current density of BK(Ca) channels and causes a shift in the steady-state inactivation relationship for Ca(v) type-L towards more hyperpolarized membrane potentials." | ( Rotundifolone-induced relaxation is mediated by BK(Ca) channel activation and Ca(v) channel inactivation. Albuquerque, JG; Araújo, DA; Araújo, IG; Barbosa-Filho, JM; Cavalcante, KV; Correia, NA; Cruz, JS; De Medeiros, IA; Dias, KL; Nunes, XP; Porto, DL; Silva, DF; Veras, RC, 2011) | 2.53 |
Class | Description |
---|---|
oxacycle | Any organic heterocyclic compound containing at least one ring oxygen atom. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (22.22) | 29.6817 |
2010's | 7 (77.78) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (20.15) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 11 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |